Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=16 Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Lymphoid Leukemia in Remission · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability
Phase 2 N=18 Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
B-cell Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 0 participants
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Phase 2 N=28 Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Phase 2 N=144 A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Chronic Lymphocytic Leukemia With 17p Deletion · Small Lymphocytic Lymphoma With 17p Deletion
Primary: Overall Response Rate — 77.8 % of participants with response by PI
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=24 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Refractory Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities
Phase 2 N=21 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Phase 2 N=134 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Phase 2 N=39 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Phase 2 N=49 Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Lymphoma, Non-Hodgkin
Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 2 N=35 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
Phase 2 N=33 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma
Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants
N/A N=158 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Phase 2 N=6 Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
Phase 2 N=89 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Malignant Neoplasm
Primary: Objective Overall Response Rate — 28.1; 53.8; 11.1 percentage of participants